Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

523
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
523
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

907
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
907

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Belumosudil for Long-Standing Refractory Chronic Graft-Versus-Host Disease: A Two-Patient Case Report.

Clinical case reports·2026
Same author

Phase II study of lenalidomide maintenance after rituximab-methotrexatebased induction therapy in primary central nervous system lymphoma.

Haematologica·2026
Same author

Anbalcabtagene autoleucel (PD-1 and TIGIT knockdown CD19 CAR-T) for relapsed/refractory large B-cell lymphoma (CRC01-01).

Blood·2026
Same author

Overcoming resistance in CD44-overexpressing myeloma through combination therapy with ATRA, bortezomib, and NK cells.

Cancer immunology, immunotherapy : CII·2026
Same author

Aerosolized Pentamidine Is an Effective Prophylaxis for <i>Pneumocystis jiroveci</i> Pneumonia in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation.

Journal of Korean medical science·2026
Same author

A novel anti-CD20, concabody, enhances immunotherapy efficacy by targeting MPZL1 and augmenting antibody-induced cell death.

Frontiers in oncology·2026
Same journal

Novel Parent Survey Measures Sensory Behaviors Incorporating Sensory Modality and Stimulus Intensity.

Heliyon·2026
Same journal

Expression of concern: "SQSTM1/p62 promotes the progression of gastric cancer through epithelial-mesenchymal transition" [Heliyon 10 (2024) e24409].

Heliyon·2026
Same journal

Expression of concern: "TL1A promotes metastasis and EMT process of colorectal cancer" [Heliyon 10 (2024) e24392].

Heliyon·2026
Same journal

Expression of concern: "Factors affecting timing of surgery following neoadjuvant chemoradiation for esophageal cancer" [Heliyon 9 (2023) e23212].

Heliyon·2026
Same journal

Expression of concern: "On stratified single-valued soft topogenous structures" [Heliyon 10 (2024) e27926].

Heliyon·2026
Same journal

Expression of concern: "Artifact removal and motor imagery classification in EEG using advanced algorithms and modified DNN" [Heliyon 10 (2024) e27198].

Heliyon·2026
See all related articles

Related Experiment Video

Updated: Jun 29, 2025

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.7K

Exploring cellular immunotherapy platforms in multiple myeloma.

Manh-Cuong Vo1,2,3, Sung-Hoon Jung2,4, Van-Tan Nguyen2

  • 1Institute of Research and Development, Duy Tan University, Danang, Viet Nam.

Heliyon
|March 25, 2024
PubMed
Summary
This summary is machine-generated.

Cellular immunotherapies show promise for multiple myeloma (MM). Marrow-infiltrating lymphocytes (MILs) and CAR T-cells offer novel ways to target cancer cells, potentially improving treatment efficacy and reducing toxicity in MM patients.

Keywords:
Cellular immunotherapyDendritic cellMarrow-infiltrating lymphocyteMultiple myelomaNatural killer cell

More Related Videos

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.1K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.4K

Related Experiment Videos

Last Updated: Jun 29, 2025

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.7K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.1K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.4K

Area of Science:

  • Hematology
  • Immunology
  • Oncology

Background:

  • Multiple myeloma (MM) remains a significant challenge, with most patients experiencing disease relapse despite therapeutic advances.
  • Novel therapeutic strategies are crucial for improving outcomes in MM patients.

Purpose of the Study:

  • To review recent innovations in cellular immunotherapies for MM.
  • To highlight the potential of marrow-infiltrating lymphocytes (MILs) and other cellular tools in treating MM.

Main Methods:

  • Review of current literature on cellular immunotherapies for MM.
  • Examination of novel approaches including CAR T-cells, MILs, NK cells, and dendritic cells.

Main Results:

  • Cellular immunotherapies, particularly CAR T-cells, are emerging as effective treatments for MM.
  • MILs represent a promising source of T-cells for adoptive therapy, demonstrating robust and specific targeting of myeloma cells.

Conclusions:

  • Innovations in cellular immunotherapies, including MILs and CAR T-cells, hold significant promise for enhancing efficacy and reducing toxicity in MM treatment.
  • Further research into these cellular tools is warranted to optimize MM therapy.